ALB and neoplasm: Guzik et al. employed a class of albumin-binding radioconjugates comprising 5-methyltetrahydrofolate as a targeting agent, which exhibited a high tumor-to-kidney ratio, yielding superior therapeutic outcomes as compared with the unmodified 177Lu-labeled conjugates 72.